The Company has Now Resumed the Clinical Development of its
Proposed Anti-Nausea Pharmaceutical Grade Version of Tauri-Gum™
NEW YORK, NY -- Dec. 24, 2020 -- InvestorsHub
NewsWire -- Tauriga Sciences, Inc. (OTCQB: TAUG)
(“Tauriga” or the “Company”), a revenue generating, diversified
life sciences company, with a proprietary line of functional
“supplement” chewing gums (Flavors: Pomegranate, Blood Orange,
Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two
ongoing Biotechnologies initiatives, today announced that it has
completed the funding of its financial obligations, pursuant to its
recently executed Master Services Agreement (the “Agreement”) with
North Carolina based Clinical Strategies & Tactics, Inc.
(“CSTI”). In a recent public statement, the Company had
confirmed its intent to fund the entirety of this Agreement, before
the end of Calendar Year 2020. With this funding now
complete, the Company is excited about its prospects for 2021 – as
it pertains to its pharmaceutical development
efforts.
On December 18, 2020 – The Company issued the following press
release: “Tauriga Sciences Inc. Enters into Master Services
Agreement with CSTI to Resume the Clinical Development of its
Anti-Nausea Pharmaceutical Grade Version of Tauri-Gum™”. Please
refer back to the December 18, 2020 press release for additional
information and details concerning the above-referenced
Agreement.
Link to Tauriga’s December 18, 2020 Press
Release: https://www.globenewswire.com/news-release/2020/12/18/2148074/0/en/Tauriga-Sciences-Inc-Enters-into-Master-Services-Agreement-with-CSTI-to-Resume-the-Clinical-Development-of-its-Anti-Nausea-Pharmaceutical-Grade-Version-of-Tauri-Gum.html
The delivery system for this proposed Pharmaceutical version is
a modified version (substantially higher concentration of CBD) of
the existing “Tauri-Gum™” chewing gum formulation based on
continued research and development.
On March 18, 2020 the Company announced that it had filed a
Provisional U.S. Patent covering its Pharmaceutical grade version
of Tauri-Gum™. This patent application, filed with the United
States Patent & Trademark Office (“U.S.P.T.O.”), is titled:
“MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS
OF TREATMENT.”
U.S. Provisional Patent Application No. 62/990,709
Below - CSTI Corporate Website:
Link: http://www.csandti.com/index.html
ABOUT TAURIGA SCIENCES INC.
Tauriga Sciences, Inc. (TAUG) is a revenue generating,
diversified life sciences company, engaged in several major
business activities and initiatives. The company
manufactures and distributes several proprietary retail products
and product lines, mainly focused on the Cannabidiol (“CBD”) and
Cannabigerol (“CBG”) Edibles market segment. The main
product line, branded as Tauri-Gum™, consists of a proprietary
supplement chewing gum that is Kosher certified, Halal certified,
and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood
Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon,
Black Currant) & (Vitamin C + Zinc “Immune Booster” Tauri-Gum™
Flavor: Pear Bellini). The Company’s commercialization
strategy consists of a broad array of retail customers,
distributors, and a fast-growing E-Commerce business segment
(E-Commerce website: www.taurigum.com). Please visit our corporate
website, for additional information, as well as inquiries,
at http://www.tauriga.com
Complementary to the Company’s retail business, are its two
ongoing biotechnology initiatives. The first one relates
to the development of a Pharmaceutical grade version of Tauri-Gum™,
for nausea regulation (specifically designed to help patients that
are subjected to ongoing chemotherapy treatment). On March 18,
2020, the Company announced that it filed a provisional U.S. patent
application covering its pharmaceutical grade version of
Tauri-Gum™. The Patent, filed with the U.S.P.T.O. is
Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND
METHODS OF TREATMENT”. The second one relates to a
collaboration agreement with Aegea Biotechnologies Inc. for the
co-development of a rapid, multiplexed, Novel Coronavirus
(COVID-19) test with superior sensitivity and
selectivity.
On October 6, 2020, the Company announced that it has been
approved to operate as a U.S. Government Vendor (CAGE CODE #
8QXV4).
On October 7, 2020 the Company disclosed a Strategic Alliance
with Think BIG, LLC, Social Impact Startup Founded by CJ Wallace,
Son of Christopher “The Notorious B.I.G.” Wallace.
The Company is headquartered in New York City and operates a
regional office in Barcelona, Spain. In addition, the
Company operates a full time E-Commerce fulfillment center located
in LaGrangeville, New York.
DISCLAIMER -- Forward-Looking Statements
This press release contains certain “forward-looking statements”
as defined by the Private Securities Litigation Reform Act of 1995
which represent management’s beliefs and assumptions concerning
future events. These forward-looking statements are often indicated
by using words such as “may,” “will,” “expects,” “anticipates,”
believes, “hopes,” “believes,” or plans, and may include statements
regarding corporate objectives as well as the attainment of certain
corporate goals and milestones. Forward-looking statements are
based on present circumstances and on management’s present beliefs
with respect to events that have not occurred, that may not occur,
or that may occur with different consequences or timing than those
now assumed or anticipated. Actual results may differ materially
from those expressed in forward looking statements due to
known and unknown risks and uncertainties, such as are not
guarantees of general economic and business conditions, the ability
to successfully develop and market products, consumer and business
consumption habits, the ability to consummate successful
acquisition and licensing transactions, fluctuations in exchange
rates, and other factors over which Tauriga has little or no
control. Many of these risks and uncertainties are discussed in
greater detail in the “Risk Factors” section of Tauriga’s Form 10-K
and other filings made from time to time with the Securities and
Exchange Commission. Such forward-looking statements are made only
as of the date of this release, and Tauriga assumes no obligation
to update forward-looking statements to reflect subsequent events
or circumstances. You should not place undue reliance on these
forward-looking statements.
Contact:
Tauriga Sciences, Inc.
555 Madison Avenue, 5th Floor
New York, NY 10022
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
cell # (917) 796 9926
Instagram: @taurigum
Twitter: @SethMShaw
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Apr 2024 to May 2024
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From May 2023 to May 2024